Recent advances in non-steroidal fxr antagonists development for therapeutic applications

Current Topics in Medicinal Chemistry

Volumn 14, Issue 19, 2014, Pages 2175-2187

  Huang, Huang ^a   Xu, Yong ^b   Zhu, Jin ^a   Li, Jian ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Humanwell Healthcare (Group) Co Ltd   (China)

Author keywords

Cholestasis; Farnesoid x receptor; Non steroidal antagonist; Pharmacological target

Indexed keywords

15 DEOXY DELTA12, 14 PROSTAGLANDIN J2; 3 [2 [2 CHLORO 4 [3 (2, 6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY] PHENYL] VINYL] BENZOIC ACID; 4 HYDROXYACETOPHENONE; 4,5,6,7 TETRAHYDROBENZO [B]THIOPHENE; AGN34; ANDROGRAPHOLIDE; ATRACTYLODES MACROCEPHALA EXTRACT; LIOTHYRONINE; NON STEROIDAL FARNESOID X RECEPTOR ANTAGONIST; POLYUNSATURATED FATTY ACID; PYRAZOLONE DERIVATIVE; RECEPTOR BLOCKING AGENT; SESQUITERPENOID; THIOPHENE DERIVATIVE; TROGLITAZONE; TUBERATOLIDE; UNCLASSIFIED DRUG; ACETOPHENONE DERIVATIVE; CELL RECEPTOR; DRUG; FARNESOID X-ACTIVATED RECEPTOR;

ARTICLE; CHOLESTEROL STONE; DIABETES MELLITUS; DRUG SCREENING; EOPLASM; METABOLIC SYNDROME X; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; HUMAN; METABOLIC DISEASES; METABOLISM; STRUCTURE ACTIVITY RELATION;

ACETOPHENONES; ANIMALS; HUMANS; METABOLIC DISEASES; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925856977     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141112101840     Document Type: Article

References (60)

1. Forman, B.M.; Goode, E.; Chen, J.; Oro, A.E.; Bradley, D.J.; Perlmann, T.; Noonan, D.J.; Burka, L.T.; McMorris, T.; Lamph, W.W.; Evans, E.M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 1995, 81, 687-693.
2. Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of bile acids and bile acid receptor in metabolic regulation. Physiol. Rev., 2009, 89, 147-191.
3. Parks, D.J.; Blanchard, S.G.; Bledsoe, R.K.; Chandra, G.; Consler, T.G.; Kliewer, S.A.; Stimmel, J.B.; Willson, T.M.; Zavacki, A.M.; Moore, D.D.; Lehmann, J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science, 1999, 284, 1365-1368.
4. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D.; Mangelsdorf, D.J.; Shan, B. Identification of a nuclear receptor for bile acids. Science, 1999, 284, 1362-1365.
5. Wang, H.; Chen, J.; Hollister, K.; Sowers, L.C.; Forman, B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell, 1999, 3, 543-553.
6. Cariou, B.; Staels, B. FXR: A promising target for the metabolic syndrome? Trends Pharmacol. Sci., 2007, 28, 236-243.
7. Chiang, Y.L.; Kimmel, R.; Weinberger, C.; Stroup, D. Farnesoid X receptor to bile acids and represses cholesterol 7-hydroxylase gene (CYP7A1) transcription. J. Biol. Chem., 2000, 275, 10918-10924.
8. Myant, N.B.; Mitropoulos, K.A. Cholesterol 7-hydroxylase. J. Lipid Res., 1977, 18, 135-153.
9. Denson, L.A.; Sturm, E.; Echevarria, W.; Zimmerman, T.L.; Makishima, M.; Mangelsdorf, D.J.; Karpen, S.J. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology, 2001, 121, 140-147.
10. Ananthanarayanan, M.; Balasubramanian, N.; Makishima, M.; Mangelsdorf, D.J.; Suchy, F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem., 2001, 276, 28857-28865.
11. Wang, Y.; Chen, W.; Moore, D.D.; Huang, W. FXR: a metabolic regulator and cell protector. Cell Res., 2008, 18, 1087-1095.
12. Fiorucci, S.; Mencarelli, A.; Palladino, G.; Cipriani, S. Bile-acidactivated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci., 2009, 30, 570-580.
13. Huang, W.; Ma, K.; Zhang, J.; Qatanani, M.; Cuvillier, J.; Liu, J.; Dong, B.; Huang, X.; Moore, D. Nuclear receptor-dependent bile acid signaling is required for normal regeneration. Science, 2006, 312, 233-236.
14. Yang, F.; Huang, X.; Yi, T.; Yen, Y.; Moore D.D.; Huang, W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res., 2007, 67, 863-867.
15. Edwards, P.A.; Kast, H.R.; Anisfeld, A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res., 2002, 43, 2-12.
16. Kalaany, N.Y.; Mangelsdorf, D.J. LXRs and FXR: the Yin and Yang of cholesterol and fat metabolism. Annu. Rev. Physiol., 2006, 68, 159-191.
17. Lee, F.Y.; Lee, H.; Hubbert, M.L.; Edwards, P.A.; Zhang, Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci., 2006, 31, 572-580.
18. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Palladino, G.; Cipriani, S. Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr. Med. Chem., 2010, 17, 139-159.
19. Fiorucci, S.; Cipriani, S.; Baldelli, F.; Mencarelli, A. Bile acidactivated receptors in the treatment of dyslipidemia and related disorders. Prog. Lipid Res., 2010, 49, 171-185.
20. Fiorucci, S.; Baldelli, F. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol., 2009, 25, 252-259.
21. Fiorucci, S.; Rizzo, G.; Donini, A.; Distrutti, E.; Santucci, L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med., 2007, 13, 298-309.
22. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P. R.; Morelli, A.; Parks D.J.; Willson, T.M. 6-Ethyl-chemodeoxycholic acid (6-CDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem., 2002, 45, 3569-3572.
23. Soisson, S.M.; Parthasarathy, G.A.; Adams, D.; Sahoo, S.; Sitlani, A.; Sparrow, C.; Cui, J.; Becker, J.W. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 5337-5342.
24. Maloney, P.R.; Parks, D.J.; Haffner, C.D.; Fivush, A.M.; Chandra, G.; Plunket, K.D.; Creech, K.L.; Moore, L.B.; Wilson, J. G.; Lewis, M.C.; Jones, S.A.; Willson, T. M. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem., 2000, 43, 2971-2974.
25. Evans, M.J.; Mahaney, P.E.; Borges-Marcucci, L.; Lai, K.; Wang, S.; Krueger, J.A.; Gardell, S.; Huard, C.; Martinez, R.; Vlasuk, G.P.; Harnish, D.C. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol., 2009, 296, G543-552.
26. Nicolaou, K.C.; Evans, R.M.; Roecker, A.J.; Hughes, R.; Downes, M.; Pfefferkorn, J.A. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem., 2003, 1, 908-920.
27. Dussault, I.; Beard, R.; Lin, M.; Hollister, K.; Chen, J.; Xiao, J.; Chandraratna, R.; Forman, B.M. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem., 2003, 278, 7027-7033.
28. Fiorucci, S.; Cipriani, S.; Mencarelli, A.; Baldelli, F.; Bifulco, G.; Zampella, A. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini-Rev. Med. Chem., 2011, 11, 753-762.
29. Renga, B.; Mencarelli, A.; D’Amore, C.; Cipriani, S.; D’Auria, M.V.; Sepe, V.; Chini, M.G.; Monti, M.C.; Bifulco, G.; Zampella, A.; Fiorucci, S. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One, 2012, 7 (1), e30443.
30. Urizar, N.L.; Liverman, A.B.; Dodds, D.T.; Silva, F.V.; Ordentlich, P.; Yan, Y.; Gonzalez, F.J.; Heyman, R.A.; Mangelsdorf, D.J.; Moore, D.D. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science, 2002, 296, 1703-1706.
31. Verma, A.K.; Khemaria, P.; Gupta, J.; Singh, D.P.; Joshi, B.S.; Roy, R.; Mishra, A.K.; Pratap, R. Bio-transformation of FXR antagonist CDRI 80/574. ARKIVOC, 2010, 2010, 1-11.
32. Sepe, V.; Bifulco, G.; Renga, B.; D'Amore, C. Fiorucci, S.; Zampella, A. Discovery of sulfated sterols from marine invertebrates as a new class of marine antagonists of farnesoid-X-receptor. J. Med. Chem., 2011, 54, 1314-1320.
33. Yu, J.; Lo, J.; Huang, L.; Zhao, L.; Metzger, E.; Adams, A.; Meinke, P.T.; Wright, S.D.; Cui, J. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J. Biol. Chem., 2002, 277, 31441-31447.
34. Nam, S.; Ko, H.; Shin, M.; Ham, J.; Chin, J.; Kim, Y.; Kim, H.; Shin, K.; Choi, H.; Kang, H. Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp. Bioorg. Med. Chem. Lett., 2006, 16, 5398-5402.
35. Carter, B.A.; Taylor, O.A.; Prendergast, D.R.; Zimmerman, T.L.; Von Furstenberg, R.; Moore, D.D.; Karpen, S.J. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr. Res., 2007, 62, 301-306.
36. Kaimal, R.; Song, X.; Yan, B.; King, R.; Deng, R. Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones. J. Pharmacol. Exp. Ther., 2009, 330, 125-134.
37. Kainuma, M.; Makishima, M.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. Bioorg. Med. Chem., 2007, 15, 2587-2600.
38. Huang, H.; Yu, Y.; Gao, Z.; Zhang, Y.; Li, C.; Xu, X.; Jin, H.; Yan, W.; Ma, R.; Zhu, J.; Shen, X.; Jiang, H.; Chen, L.; Li, J. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists. J. Med. Chem., 2012, 55, 7037-7053.
39. Owsley, E.; Chiang, Y.L. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7-hydroxylase gene. Biochem. Biophys. Res. Commun., 2003, 304, 191-195.
40. Burris, H.P.; Montrose, C.; Houck, K.A.; Osborne, H.E.; Bocchinfuso, W.P.; Yaden, B.C.; Christine, C.; Cheng, C.; Zink, R.W.; Barr, R.J.; Hepler, C.D.; Krishnan, V.; Bullock, H.A.; Burris, L.L.; Galvin, R.J.; Bramlett, K.; Stayrook, K.R. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol., 2005, 67, 948-954.
41. Cui, J.; Huang, L.; Zhao, A.; Lew, J.; Yu, J.; Sahoo, S.; Meinke, P.T.; Royo, I.; Pelaez, F.; Wright, S.D. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem., 2003, 278, 10214-10220.
42. Storlien, L.H.; Kraegen, E.W.; Chisholm, D.J.; Ford, G.L.; Bruce, D.G.; Pascoe, W.S. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science, 1987. 237, 885-888.
43. Nestel, P. J. Effects of N-3 fatty acids on lipid metabolism. Annu. Rev. Nutr., 1990, 10, 149-167.
44. Jump, D.B., Clarke, S.D. Regulation of gene expression by dietary fat. Annu. Rev. Nutr., 1999. 19, 63-90.
45. Zhao, A.; Yu, J.; Lew, J.; Huang, L.; Wright, D.S.; Cui, J. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA. Cell. Biol., 2004, 23. 519-526.
46. Choi, H.; Hwang, H.; Chin, J.; Kim, E.; Lee, J.; Nam, S.; Lee, B.; Rho, B.; Kang, H. Tuberatolides, potent FXR antagonists from the Korean marine Tunicate Botryllus tuberatus. J. Nat. Prod., 2011, 74, 90-94.
47. Tsai, C.; Liang, J.; Lin, H. Sesquiterpenoids from Atractylodes macrocephala act as farnesoid X receptor and progesterone receptor modulators. Bioorg. Med. Chem. Lett., 2012, 22, 2326-2329.
48. Li, C.; He, L.; Hu, Y. Asian J. Pharmacodyn. Pharmacokinet., 2007, 7, 283.
49. Bohlmann, F.; Dutta, L.N.; Knauf, W.; Robinson, H.; King, R.M. Naturally occuring terpene derivatives. 241. New sesquiterpene lactones from Aster umbellatus. Phytochemistry, 1980, 19, 433-436.
50. Xu, X.; Lu, Y.; Chen, L.; Chen, J.; Luo, X.; Shen, X. Identification of 15d-PGJ2 as an antagonist of farnesoid X receptor: molecular modeling with biological evaluation. Steroids, 2013, 78, 813-822.
51. Liu, Z.; Law, W.; Wang, D.; Nie, X.; Sheng, D.; Song, G.; Guo, Kai.; Wei, P.; Ouyang, P.; Wong, C.; Zhou G. Synthesis and discovery of andrographolide derivatives as non-steroidal farnesoid X receptor (FXR) antagonists. RSC Adv., 2014, 4, 13533-13545.
52. Fu, J.; Si, P.; Zheng, M.; Chen, L.; Shen, X.; Tang, Y.; Li, W. Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking. Bioorg. Med. Chem. Lett., 2012, 22, 6848-6853.
53. Liu, P.; Xu, X.; Chen, L.; Ma, L.; Shen, X.; Hu, L. Discovery and SAR study of hydroxyacetophenone derivatives as potent, nonsteroidal farnesoid X receptor (FXR) antagonists. Bioorg. Med. Chem., 2014, 22, 1596-1607.
54. Hashimoto, Y.; Miyachi, H. Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis. Bioorg. Med. Chem., 2005, 13, 5080-5093.
55. Maloney, P.R.; Parks, D.J.; Haffner, C.D.; Fivush, A.M.; Chandra, G; Plunket, K.D.; Creech, K.L.; Moore, L.B.; Wilson, J.G.; Lewis, M.C.; Jones, S.A.; Willson, T.M. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem., 2000, 43, 2971-2974.
56. Eyrolles, L.; Kawachi, E.; Matsushima, Y.; Nakajima, O.; Kagechika, H.; Hashimoto, Y.; Shudo, K. Retinoid antagonists: molecular design based on the ligand superfamily concept. Med. Chem. Res., 1992, 2, 361-367.
57. Eyrolles, L.; Kagechika, H.; Kawachi, E.; Fukasawa, H.; Iijima, T.; Matsushima, Y.; Hashimoto, Y.; Shudo, K. Retinobenzoic acids. 6. Retinoid antagonists with a heterocyclic ring. J. Med. Chem., 1994, 37, 1508-1517.
58. Amano, Y.; Shimada, M.; Miura, S.; Adachi, R.; Tozawa, R. Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates. Eur. J. Pharmacol., 2014, 723, 108-115.
59. Amano, Y.; Shimada, M.; Miura, S.; Adachi, R.; Tozawa, R. Antidyslipidemic effects of a farnesoid X receptor antagonist in primates. Life. Sci., 2014, 106, 25-31.
60. Di Leva, F.S.; Festa, C.; D’Amore, C.; De Marino, S.; Renga, B.; D’Auria, M.V.; Novellino, Ettore.; Limongelli, Vittorio.; Zampella, A; Fiorucci, Stefano. Binding mechanism of the farnesoid X receptor marine antagonist Suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. J. Med. Chem., 2013, 56, 4701-4717.